Development and validation of a measure of informed choice for XXXX undergoing non-invasive prenatal testing for @entity2007 .

@entity1 @entity2007 @entity3
UNASSIGNED: @entity3 ( @entity3 ) using cell-free DNA for @entity2007 is a highly accurate screening test; however, concerns exist around the potential for routinisation of testing. The multidimensional measure of informed choice (MMIC) is a quantitative instrument developed to assess informed choice for Down syndrome screening (DSS). We have validated a modified MMIC for @entity3 and measured informed choice among @entity1 offered @entity3 in a public health service. The measure was distributed to @entity1 recruited across eight maternity units in the United Kingdom who had accepted DSS. Construct validity was assessed by simultaneously conducting qualitative interviews. Five hundred and eighty-five questionnaires were completed and 45 interviews conducted after blood-draw (or equivalent for those that declined @entity3 ). The measure demonstrated good internal consistency and internal validity. Results indicate the vast majority of @entity1 (89%) made an informed choice; 95% were judged to have good knowledge, 88% had a positive attitude and 92% had deliberated. Of the 11% judged to have made an uninformed choice, 55% had not deliberated, 41% had insufficient knowledge, and 19% had a negative attitude. Ethnicity (OR=2.78, P=0.003) and accepting @entity3 (OR=16.05, P=0.021) were found to be significant predictors of informed choice. The high rate of informed choice is likely to reflect the importance placed on the provision of pre-test counselling in this study. It will be vital to ensure that this is maintained once @entity3 is offered in routine clinical practice.European Journal of @entity1 Genetics advance online publication, 28 October 2015; doi:10.1038/ejhg.2015.207.
